Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 8 | 2019 | 344 | 1.810 |
Why?
|
| Immunotherapy, Adoptive | 11 | 2026 | 950 | 1.570 |
Why?
|
| Dendritic Cells | 8 | 2011 | 437 | 1.220 |
Why?
|
| T-Lymphocytes | 7 | 2026 | 1705 | 0.910 |
Why?
|
| Cancer Vaccines | 6 | 2011 | 191 | 0.800 |
Why?
|
| CD40 Antigens | 3 | 2011 | 25 | 0.670 |
Why?
|
| Chemokine CCL5 | 2 | 2010 | 53 | 0.610 |
Why?
|
| Antigens, CD19 | 2 | 2024 | 191 | 0.610 |
Why?
|
| Neoplasms | 6 | 2024 | 2968 | 0.610 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2019 | 495 | 0.600 |
Why?
|
| Transduction, Genetic | 3 | 2016 | 279 | 0.540 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 149 | 0.540 |
Why?
|
| K562 Cells | 3 | 2019 | 97 | 0.530 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 275 | 0.520 |
Why?
|
| Cell Proliferation | 4 | 2016 | 2477 | 0.390 |
Why?
|
| Multiple Myeloma | 1 | 2015 | 190 | 0.370 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 849 | 0.360 |
Why?
|
| Oncolytic Viruses | 2 | 2009 | 75 | 0.350 |
Why?
|
| Adenoviridae | 5 | 2019 | 586 | 0.330 |
Why?
|
| Interleukin-15 | 3 | 2024 | 105 | 0.330 |
Why?
|
| Adjuvants, Immunologic | 2 | 2011 | 390 | 0.300 |
Why?
|
| Cell Movement | 2 | 2010 | 882 | 0.280 |
Why?
|
| Immunotherapy | 3 | 2010 | 760 | 0.270 |
Why?
|
| Genetic Vectors | 4 | 2019 | 906 | 0.250 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 141 | 0.250 |
Why?
|
| Flow Cytometry | 4 | 2017 | 771 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 462 | 0.240 |
Why?
|
| Lymphocyte Activation | 4 | 2017 | 633 | 0.230 |
Why?
|
| Genetic Therapy | 1 | 2010 | 725 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 198 | 0.220 |
Why?
|
| Antigens, Neoplasm | 2 | 2026 | 402 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 40 | 0.220 |
Why?
|
| Receptors, CXCR4 | 1 | 2005 | 71 | 0.210 |
Why?
|
| Blood Component Removal | 2 | 2016 | 35 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 1270 | 0.210 |
Why?
|
| Gangliosides | 1 | 2024 | 73 | 0.200 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 64 | 0.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2026 | 187 | 0.200 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 665 | 0.190 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 710 | 0.180 |
Why?
|
| Sarcoma | 1 | 2024 | 212 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 208 | 0.170 |
Why?
|
| Humans | 27 | 2026 | 132041 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 153 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 792 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1811 | 0.160 |
Why?
|
| Blotting, Western | 2 | 2015 | 1019 | 0.160 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 2011 | 6 | 0.160 |
Why?
|
| Interleukin-12 | 3 | 2011 | 124 | 0.160 |
Why?
|
| Cell Transplantation | 2 | 2017 | 36 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2026 | 743 | 0.150 |
Why?
|
| Retroviridae | 1 | 2019 | 182 | 0.150 |
Why?
|
| Leukemia | 1 | 2022 | 375 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 314 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1614 | 0.140 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 51 | 0.140 |
Why?
|
| Cell Differentiation | 5 | 2017 | 1950 | 0.130 |
Why?
|
| Cell Survival | 2 | 2012 | 849 | 0.130 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 3703 | 0.130 |
Why?
|
| Lipopolysaccharides | 2 | 2010 | 303 | 0.130 |
Why?
|
| CD28 Antigens | 1 | 2017 | 76 | 0.130 |
Why?
|
| CD3 Complex | 1 | 2017 | 93 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 683 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 647 | 0.120 |
Why?
|
| Feeder Cells | 1 | 2016 | 9 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 986 | 0.120 |
Why?
|
| Mice | 9 | 2019 | 18394 | 0.120 |
Why?
|
| Animals | 11 | 2019 | 34262 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2024 | 418 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1279 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2006 | 659 | 0.100 |
Why?
|
| Antigen-Presenting Cells | 1 | 2014 | 121 | 0.100 |
Why?
|
| Organic Chemicals | 2 | 2011 | 58 | 0.100 |
Why?
|
| 4-1BB Ligand | 1 | 2012 | 11 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 79 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 2657 | 0.090 |
Why?
|
| Cytokines | 2 | 2017 | 1356 | 0.090 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 11 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2019 | 275 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2011 | 11 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 115 | 0.090 |
Why?
|
| Female | 11 | 2026 | 71380 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 583 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 39 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2011 | 97 | 0.080 |
Why?
|
| Tumor Escape | 1 | 2010 | 63 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 261 | 0.080 |
Why?
|
| Chemotaxis | 1 | 2010 | 62 | 0.080 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2009 | 3 | 0.080 |
Why?
|
| beta-Defensins | 1 | 2009 | 12 | 0.080 |
Why?
|
| Young Adult | 2 | 2024 | 10128 | 0.070 |
Why?
|
| Middle Aged | 5 | 2026 | 28946 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2014 | 580 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2026 | 13025 | 0.070 |
Why?
|
| COS Cells | 1 | 2009 | 249 | 0.070 |
Why?
|
| Ovalbumin | 1 | 2009 | 113 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2011 | 4733 | 0.070 |
Why?
|
| Child | 4 | 2024 | 26361 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2011 | 681 | 0.070 |
Why?
|
| Aged | 4 | 2026 | 21288 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1062 | 0.070 |
Why?
|
| Receptors, CCR7 | 1 | 2007 | 21 | 0.070 |
Why?
|
| Cell Line | 2 | 2011 | 2591 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2009 | 90 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2024 | 15089 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 2007 | 114 | 0.070 |
Why?
|
| Male | 8 | 2026 | 65425 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2007 | 121 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2007 | 156 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2017 | 237 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2009 | 542 | 0.060 |
Why?
|
| Adolescent | 2 | 2024 | 21018 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2017 | 337 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 345 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 512 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 23 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2005 | 231 | 0.050 |
Why?
|
| Vidarabine | 1 | 2024 | 91 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 482 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2005 | 310 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 123 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 277 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 986 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 646 | 0.050 |
Why?
|
| Adult | 4 | 2026 | 31747 | 0.050 |
Why?
|
| Centrifugation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2011 | 4696 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 440 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2023 | 358 | 0.040 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 83 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 359 | 0.040 |
Why?
|
| Risk Factors | 1 | 2015 | 11020 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 677 | 0.040 |
Why?
|
| Apoptosis | 1 | 2006 | 1863 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4540 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1240 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 504 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 15 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2011 | 450 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 127 | 0.040 |
Why?
|
| Disease Progression | 1 | 2005 | 2229 | 0.030 |
Why?
|
| Recurrence | 1 | 2022 | 1484 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2011 | 3864 | 0.030 |
Why?
|
| Lymphoma | 2 | 2014 | 331 | 0.030 |
Why?
|
| Ligands | 1 | 2019 | 487 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 84 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2017 | 46 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 2020 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 695 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5124 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2014 | 55 | 0.030 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 59 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 160 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2014 | 114 | 0.030 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2014 | 62 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 703 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2014 | 108 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 127 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 302 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 557 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2024 | 6539 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5287 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2014 | 395 | 0.020 |
Why?
|
| Enzyme Assays | 1 | 2011 | 11 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 54 | 0.020 |
Why?
|
| Carcinoma | 1 | 2014 | 284 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2011 | 52 | 0.020 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2011 | 21 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 180 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 38 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2011 | 62 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 725 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 240 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 112 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 363 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 164 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 205 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 555 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 212 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 417 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 13343 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 810 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 1320 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1674 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2006 | 16 | 0.020 |
Why?
|
| Biosynthetic Pathways | 1 | 2006 | 31 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6930 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2364 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2947 | 0.010 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 277 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17748 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1419 | 0.010 |
Why?
|
| Melanoma | 1 | 2006 | 922 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 905 | 0.010 |
Why?
|